Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
L'Oreal USA, In the Matter of
Pinnacle Payment Services, LLC
Akorn, Inc., In the Matter of
Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn’s proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be anticompetitive. According to the FTC’s complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin and there are no viable substitutes for rifampin as a course of treatment for tuberculosis. The FTC’s proposed settlement with Akorn requires the company to divest its Abbreviated New Drug Application for generic injectable rifampin – which is currently pending before the Food and Drug Administration – to Watson Laboratories, Inc.
Icon Health and Fitness, Inc.; IHF Holdings, Inc.; and IHF Capital, Inc., In the Matter of
Lornamead, Inc., In the Matter of
Intermundo Media, LLC (Delta Prime Refinance)
Engineered Plastic Systems, LLC, In the Matter of
Chairwoman Edith Ramirez Media Statement on FTC Suing Pharmaceutical Companies for Illegally Blocking Consumer Access to Lower-Cost Versions of AndroGel
Actavis PLC and Forest Laboratories, In the Matter of
Pharmaceutical companies Actavis plc and Forest Laboratories, Inc. agreed to sell or relinquish their rights to four generic pharmaceuticals that treat hypertension, angina, cirrhosis, and prevent seizures to settle FTC charges that Actavis’s acquisition of Forest likely would be anticompetitive. According to the FTC’s complaint, Actavis’s acquisition of Forest, as originally proposed, would violate federal antitrust laws by reducing competition in the markets for three current generic products. In addition, the FTC’s complaint also alleges that the proposed transaction would delay the introduction of another generic drug. Under the proposed FTC settlement order, the companies have agreed to relinquish their rights to market generic diltiazem hydrochloride (AB4) to Valeant Pharmaceuticals International, Inc.; sell generic ursodiol and generic lamotrigine ODT to Impax Laboratories, Inc.; and sell generic propranolol hydrochloride to Catalent Pharma Solutions, Inc. Under the terms of the proposed settlement, Actavis and Forest must ensure the viability, marketability, and competitiveness of the drugs that are
being divested until they are sold.
Hertz Global Holdings, Inc., In the Matter of
Hertz Global Holdings, Inc. agreed to sell its Advantage Rent A Car business, as well as the rights to operate 29 Dollar Thrifty on-airport locations around the country, to settle charges that Hertz’s $2.3 billion acquisition of Dollar Thrifty would have been harmed competition in 72 airport markets throughout the United States.